Table 2 Association of STK3 rs7827435 with BCR in localized prostate cancer patients treated with RP
 | Univariate analysis | Multivariate analysisa | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene SNP | Discovery | Replication | Combined | Â | Discovery | Replication | Combined | |||||||||
Genotype | No BCR | BCR | HR (95% CI) | P | No BCR | BCR | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P |
STK3 rs7827435 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
AA | 40 | 23 | 1.00 | Â | 25 | 29 | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â | 1.00 | Â |
AT | 87 | 38 | 0.80 (0.47–1.34) | 0.387 | 53 | 59 | 1.10 (0.70–1.72) | 0.690 | 0.96 (0.68–1.36) | 0.83 | 0.93 (0.54–1.59) | 0.785 | 0.90 (0.57–1.41) | 0.635 | 0.91 (0.64–1.29) | 0.61 |
TT | 40 | 12 | 0.49 (0.25–0.99) | 0.048 | 24 | 16 | 0.60 (0.32–1.10) | 0.097 | 0.55 (0.34–0.86) | 0.01 | 0.43 (0.20–0.89) | 0.024 | 0.49 (0.26–0.93) | 0.028 | 0.46 (0.29–0.76) | 0.002 |
AT/TT vs AA |  |  | 0.69 (0.42–1.14) | 0.147 |  |  | 0.93 (0.60–1.42) | 0.725 | 0.82 (0.59–1.13) | 0.23 | 0.73 (0.44–1.21) | 0.220 | 0.76 (0.49–1.18) | 0.220 | 0.75 (0.54–1.04) | 0.08 |
TT vs AA/AT |  |  | 0.57 (0.31–1.07) | 0.079 |  |  | 0.56 (0.33–0.96) | 0.034 | 0.56 (0.38–0.84) | 0.005 | 0.45 (0.23–0.87) | 0.018 | 0.53 (0.30–0.93) | 0.026 | 0.49 (0.32–0.76) | 0.001 |
Trend |  |  | 0.72 (0.52–1.00) | 0.048 |  |  | 0.81 (0.62–1.07) | 0.133 | 0.77 (0.63–0.95) | 0.01 | 0.70 (0.50–0.97) | 0.030 | 0.73 (0.55–0.98) | 0.033 | 0.72 (0.58–0.89) | 0.003 |